ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort

  • 期刊论文

  • 发表日期：

    2024年12月12日

查看全文
  • Dhamidhu Eratne,
  • Qiao-Xin Li,
  • Courtney Lewis,
  • Christa Dang,
  • Matthew J. Y. Kang,
  • Jasleen Grewal,
  • Samantha Loi,
  • Mark Walterfang,
  • Andrew H. Evans,
  • Charles B. Malpas,
  • Steve Pedrini,
  • Ralph Martins,
  • Pratishtha Chatterjee,
  • Henrik Zetterberg,
  • Kaj Blennow,
  • Samuel F. Berkovic,
  • Alexander F. Santillo,
  • Steven Collins,
  • Colin L. Masters,
  • Dennis Velakoulis,
  • Hannah Dobson,
  • Rosie Watson,
  • Nawaf Yassi,
  • Terence J. O’Brien,
  • Patrick Kwan,
  • Christos Pantelis,
  • Oskar Hansson,
  • Shorena Janelidze,
  • Christiane Stehmann,
  • Christopher Fowler,
  • Sarah Farrand,
  • Michael Keem,
  • Cath Kaylor-Hughes,
  • Richard Kanaan,
  • Piero Perucca,
  • Rashida Ali,
  • Anna King,
  • Jane Gunn,
  • Tianxin Pan,
  • Ilias Goranitis,
  • Steve Simpson-Yap,
  • Tomas Kalincik

摘要

Objective

We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and neurofilament light (NfL) to distinguish biomarker-defined Alzheimer disease (AD) from non-AD conditions, in a heterogenous clinical cohort of younger people.

Methods

Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other CSF profiles (Other).

Results

Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 Other. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to Other (3.67 vs 1.12 pg/mL, 3.87 vs 1.79 pg/mL, 189 vs 80 pg/mL, respectively). ptau217 distinguished AD from Other with 90% accuracy (88% specificity, 100% sensitivity). ptau217 also demonstrated strong diagnostic performance for clinically diagnosed AD.

Conclusions

Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient’s symptoms.